Etodolac (Lodine®): Profile of an established selective COX-2 inhibitor
- 1 May 2001
- journal article
- Published by Springer Nature in Inflammopharmacology
- Vol. 9 (1-2) , 63-70
- https://doi.org/10.1163/156856001300248335
Abstract
Etodolac was developed in a search for a novel NSAID with an improved efficacy/side effect profile and was launched in the UK in 1985 for the acute and chrKeywords
This publication has 18 references indexed in Scilit:
- CYCLOOXYGENASES 1 AND 2Annual Review of Pharmacology and Toxicology, 1998
- Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitorBritish Journal of Pharmacology, 1997
- Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors, using sensitive microsomal and platelet assaysCanadian Journal of Physiology and Pharmacology, 1997
- Toward an Understanding of NSAID-Related Adverse Events: The Contribution of Longitudinal DataScandinavian Journal of Rheumatology, 1996
- Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1European Journal of Pharmacology, 1995
- Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1990
- Large-scale open trials with etodolac (Lodine®) in France: An assessment of safetyRheumatology International, 1990
- Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandinsRheumatology International, 1990
- EVALUATION OF THE EFFICACY AND COMPARATIVE EFFECTS ON GASTRIC AND DUODENAL MUCOSA OF ETODOLAC AND NAPROXEN IN PATIENTS WITH RHEUMATOID ARTHRITIS USING ENDOSCOPYRheumatology, 1989
- The Effect of Etodolac Administration on Renal Function in Patients With ArthritisThe Journal of Clinical Pharmacology, 1986